- Home
- SAIH vs SPRB Comparison
SAIH vs SPRB Comparison
Compare SAIH & SPRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAIH
- SPRB
- Stock Information
- Founded
- SAIH 2019
- SPRB 2014
- Country
- SAIH Singapore
- SPRB United States
- Employees
- SAIH N/A
- SPRB N/A
- Industry
- SAIH
- SPRB Medicinal Chemicals and Botanical Products
- Sector
- SAIH
- SPRB Health Care
- Exchange
- SAIH NYSE
- SPRB Nasdaq
- Market Cap
- SAIH 17.1M
- SPRB 15.7M
- IPO Year
- SAIH N/A
- SPRB 2020
- Fundamental
- Price
- SAIH $0.70
- SPRB $0.36
- Analyst Decision
- SAIH
- SPRB Hold
- Analyst Count
- SAIH 0
- SPRB 7
- Target Price
- SAIH N/A
- SPRB $2.17
- AVG Volume (30 Days)
- SAIH 89.5K
- SPRB 595.7K
- Earning Date
- SAIH 11-13-2024
- SPRB 03-12-2025
- Dividend Yield
- SAIH N/A
- SPRB N/A
- EPS Growth
- SAIH N/A
- SPRB N/A
- EPS
- SAIH N/A
- SPRB N/A
- Revenue
- SAIH $6,954,000.00
- SPRB $7,101,000.00
- Revenue This Year
- SAIH N/A
- SPRB N/A
- Revenue Next Year
- SAIH N/A
- SPRB N/A
- P/E Ratio
- SAIH N/A
- SPRB N/A
- Revenue Growth
- SAIH N/A
- SPRB N/A
- 52 Week Low
- SAIH $0.54
- SPRB $0.34
- 52 Week High
- SAIH $1.80
- SPRB $5.95
- Technical
- Relative Strength Index (RSI)
- SAIH N/A
- SPRB 37.97
- Support Level
- SAIH N/A
- SPRB $0.34
- Resistance Level
- SAIH N/A
- SPRB $0.39
- Average True Range (ATR)
- SAIH 0.00
- SPRB 0.03
- MACD
- SAIH 0.00
- SPRB 0.00
- Stochastic Oscillator
- SAIH 0.00
- SPRB 20.73
About SAIH SAIHEAT LIMITED
Saiheat Ltd develops technologies for the advanced Computing Center Ecosystem (ACCE), a next-gen computing center featuring high-performance servers, advanced liquid cooling, and systems for capturing and recycling computing heat. It aims to reduce the carbon footprint of Bitcoin mining and AI operations.
About SPRB Spruce Biosciences Inc.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).